Target Mast cells
K |
|||
| (4 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
| + | {{up|PHA Biologicals}} | ||
'''bradykinin antagonists''' ''Icatibant, Noscapine''' | '''bradykinin antagonists''' ''Icatibant, Noscapine''' | ||
| Zeile 5: | Zeile 6: | ||
{{tp|p=32526773|t=2020. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.|pdf=|usr=008}} | {{tp|p=32526773|t=2020. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.|pdf=|usr=008}} | ||
{{tp|p=32359101|t=2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications |pdf=|usr=}} | {{tp|p=32359101|t=2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications |pdf=|usr=}} | ||
| − | + | {{tp|p=32504925|t=2020. What would Sergio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?|pdf=|usr=009}} | |
'''Apremilast''' | '''Apremilast''' | ||
| Zeile 18: | Zeile 19: | ||
'''Cromoglycate''' | '''Cromoglycate''' | ||
{{tp|p=32460208|t=2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.|pdf=|usr=009}} | {{tp|p=32460208|t=2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.|pdf=|usr=009}} | ||
| + | {{tp|p=32581809|t=2020. Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19.|pdf=|usr=011}} | ||
| + | |||
'''H1 antihistamines''' | '''H1 antihistamines''' | ||
'''Famotidine''' | '''Famotidine''' | ||
{{tp|p=32579065|t=2020. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.|pdf=|usr=010}} | {{tp|p=32579065|t=2020. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.|pdf=|usr=010}} | ||
| + | {{tp|p=32599963|t=2020. Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.|pdf=|usr=011}} | ||
| + | |||
| + | {{tp|p=32446698|t=2020. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.|pdf=|usr=008}} | ||
| + | {{tp|p=32499303|t=2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.|pdf=|usr=007}} | ||
Aktuelle Version vom 18. Januar 2021, 20:46 Uhr
| PHA Biologicals |
'bradykinin antagonists Icatibant, Noscapine
| 32337769 2020. (tt bradykinin) Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2 |
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications
32526773 2020. Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.
32359101 2020. A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications
32504925 2020. What would Sergio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
Apremilast
32449265 2020. Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.
Montelukast
32492562 2020. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
32416408 2020. As a potential treatment of COVID-19: Montelukast.
32586154 2020. Montelukast's ability to fight COVID-19 infection.
Cromoglycate
32460208 2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.
32581809 2020. Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19.
H1 antihistamines
Famotidine
32579065 2020. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.
32599963 2020. Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.
32446698 2020. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
32499303 2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
